FDA approves GSK’s Breo Ellipta to treat COPD

The FDA has approved GlaxoSmithKline and Theravance’s Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruct…

---

GSK-Theravance’s Breo wins FDA approval for COPD

GlaxoSmithKline and Theravance obtained FDA approval to market Breo, a combination of the new beta agonist vilanterol and flu -More- …

---

UPDATED: GlaxoSmithKline gains blockbuster FDA approval of lung drug Breo

GlaxoSmithKline and Theravance have won FDA approval for their drug Breo Ellipta for treating chronic obstructive pulmonary disease, the third-biggest killer of Americans, the agency announced. The ap…

---

Theravance-GSK’s COPD drug wins support of FDA panel

A panel of FDA advisers endorsed the approval of GlaxoSmithKline and Theravance's Breo Ellipta as a treatment for chronic obs -More- Xcellerate® Clinical Trial Optimization® When a l…

---